Skip to main content

Table 3 Clinicopathological features, tumor markers, and patient survival (univariate analysis)

From: Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells

Variable 5-Year DFS HR (95 % CI) P-value 5-Year OS HR (95 % CI) P-value
A. univariate analysis     
     Age (≥55 years vs <55 years) 0.77(0.43-1.36) 0.3659 0.76(0.38-1.51) 0.4313
     Pathology (serous vs other) 0.51(0.24-1.09) 0.0833 0.69(0.29-1.67) 0.4100
     Histological grade (poor vs well/moderate) 0.61(0.34-1.07) 0.0859 0.73(0.37-1.43) 0.3587
     FIGO stage (III/IV vs I/II) 5.95(1.44-24.55) 0.0137 8.41(1.14-62.03) 0.0368
     Malignant cells in ascites (yes vs no) 1.96(1.09-3.51) 0.0242 1.59(0.79-3.20) 0.1913
     Lymph node metastasis (yes vs no) 3.29(1.99-6.03) 0.0001 2.55(1.28-5.07) 0.0076
     Liver or lung metastasis (yes vs no) 4.28(2.35-7.80) <0.001 3.62(1.81-7.25) 0.0003
     Residual tumor (>1 vs <1) 2.04(1.14-3.66) 0.0164 1.81(0.90-3.63) 0.0950
     TLR4 (high vs low) 1.78(0.79-4.02) 0.1657 1.68(0.67-4.19) 0.2685
     MyD88 (positive vs negative) 0.10(0.02-0.41) 0.0014 0.09(0.01-0.67) 0.0185
B. multivariate analysis     
     FIGO stage (III/IV vs I/II) 4.57(1.04-20.17) 0.0446 7.89(1.03-58.90) 0.0468
     Malignant cells in ascites (yes vs no) 1.38(0.73-2.60) 0.3255 —— ——
     Lymph node metastasis (yes vs no) 1.25(0.62-2.52) 0.5315 0.94(0.43-2.05) 0.8713
     Liver or lung metastasis (yes vs no) 2.21(1.05-4.69) 0.0380 2.47(1.13-5.41) 0.0237
     Residual tumor (>1 vs <1) 1.04(0.54-1.99) 0.9082 —— ——
     MyD88 (high vs low) 0.11(0.23-0.47) 0.0027 0.12(0.02-0.89) 0.0382
  1. Abbreviations: DFS = disease-free survival; HR = hazard ratio; CI = confidence interval; OS = overall survival; FIGO = International Federation of Gynecology and Obstetrics; TLR4 = Toll-like receptor 4; MyD88 = myeloid differentiation factor 88. Bold values indicate P < 0.05.